		  Patent Term Extended Under 35 U.S.C.   156
   
   An interim extension of the term of U.S. Patent No. 4,048,306 has been
granted under 35 UC.    156(e)(2) for a period of one year from the
first extended expiration date of the patent. The patent was previously
extended for one year under 35 U.S.C.   156(d)(5). See 1167 OG 14,
October 4, 1994. An application for patent term extension was filed by
Eli Lilly and Company, on behalf of the patent owner Boehringer
Ingelheim GmbH, based on approval of the product "DYNABAC" by the Food
and Drug Administration.
